


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE DISTRIBUTION AGREEMENT FOR BOTUNLINUM TOXIN LETYBO® RENEWED UNTIL END OF THE YEAR 2030

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the exclusive distribution agreement with the Korean biopharmaceutical company Hugel, Inc. (“**Hugel**”) for type A botulinum toxin for injection (brand name: Letybo®, dose: 100U and 50U) (“**Letybo**®” or the “**Product**”), as confirmed by both parties of the agreement, was renewed until the end of the year 2030.

Letybo® is the fourth botulinum toxin product approved for marketing in China and the only Korean botulinum toxin product approved in China. The Product is developed and manufactured by Hugel and has been the No.1 botulinum toxin product in Korea for eight consecutive years in terms of the market share. Since the approval of Letybo® in China in 2020 and its official launch in the market for sale in 2021, the Product has been recognized by a large number of aesthetic consumers for its high quality and cost-effective features. In the first half of 2024, sales revenue of Letybo® in China continued to grow at a high rate, with a year-on-year increase of more than 50%. According to market data, the market share of Letybo® in China has exceeded 10%.

As the most important and exclusive strategic partner of Hugel in China, the Group is committed to continuously consolidate and strengthen its in-depth strategic cooperation with Hugel in China, including but not limited to the products currently under cooperation, namely, Letybo® and the hyaluronic acid Persnica™. The Group believes that the close strategic cooperation with Hugel will help maximize the value for shareholders of both parties, while the Group is confident that together with Hugel, we will achieve the goal of building Letybo® into a leading botulinum toxin brand in China in the near future.

About Meiyan Space

Meiyan Space is a new type of “one-stop” medical aesthetic platform incubated by Sihuan Pharmaceutical, through the globalization layout, comprehensive and professional medical aesthetic product matrix, product research and development, registration, production and sales of an integrated structure, is dedicated to building a leading company featuring full medical aesthetics product matrix in China by leveraging the rigour and innovation of pharmaceutical companies.

Meiyan Space continues to build a complete product matrix covering the whole life cycle needs of beauty lovers through the dual-engine drive of “self-research + BD”, with more than 60 products in the pipeline, covering the basic categories of light medical aesthetic, including fillers, contouring, support, optoelectronic equipment and skin management. Meanwhile, Meiyan Space has strong independent research and development and technology transfer strength, the professional BD team and R&D team in China and abroad can quickly promote the research and development and launching of independent and imported medical aesthetic products. At present, Meiyan Space has established three production bases globally, with perfect quality management system and effective risk management for the whole life cycle of products. Its experienced medical aesthetic sales team, nationwide sales network and well developed system can quickly promote the sales of products. Most of the sales team members of Meiyan Space come from multinational medical aesthetic and pharmaceutical enterprises, with rich experience in the sales of medical aesthetic products, and work closely with dozens of agents, the sales network has covered more than 360 cities and more than 5,900 medical aesthetic institutions.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 27 September 2024

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.